We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Rapid Tests Assessed for Chronic Chagas Disease

By LabMedica International staff writers
Posted on 18 Jun 2019
Chagas disease (CD) is a parasitic disease that can affect seriously the health status of affected individuals. More...
People with CD, mainly living in remote areas of Latin America, often face major barriers to the disease recognition, diagnosis and treatment. In the U.S., there are estimated to be at least 300,000 cases of chronic Chagas disease among people originally from countries of Latin America where Chagas disease is endemic.

Rapid diagnostic tests (RDTs) are easy-to-use and less technically and time demanding than classical serological techniques. Remarkably, many of them can be performed on serum or with a very little volume of whole blood, and they can be stored on the shelf for longer than a year. Their large-scale use could contribute to increased access to diagnosis, better treatment coverage, and a reduction of disease transmission.

Tropical medicine specialists working with the Sacro Cuore - Don Calabria Hospital (Verona, Italy) undertook a comprehensive search of various databases last up-dates on the July 1, 2017, without language or date limits. Non-electronic sources have been also searched. This review included clinical studies with cohort recruitment of individuals at risk of Trypanosoma cruzi exposure, without age limits; adequate reference standards for the diagnosis of CD. Geographical area, commercial brand, disease prevalence, study size, and risk of bias were explored as possible source of heterogeneity.

The team included in the analysis 12 datasets, comprising a total of 6,123 participants, from 101 to 1,913 individuals, tested in single studies and six different RDTs were evaluated. The pooled sensitivity and specificity of the RDTs resulted 96.6% (95% CI 91.3–98.7%) and 99.3% (95% CI 98.4–99.7%), respectively. Test accuracy was particularly good in endemic areas (98.07%/99.03% of sensitivity/specificity, respectively). One test, Chagas Stat-Pak (Chembio Diagnostic Systems, Medford, NY, USA) showed an overall sensitivity of 97% (95% CI 87.6–99.3) and specificity of 99.4% (95% CI 98.6–99.8).

The authors concluded that the accuracy of all RDTs studied can be considered sufficiently good to recommend their use in endemic settings, particularly in the Southern Cone of Latin America, in order to increase access to diagnosis. The Stat-Pak test can be recommended for use in screening surveys when the expected prevalence is moderately high or high, in the setting of Southern Cone or for migrants from that area in case of non-endemic countries. The study was published on May 31, 2019, in the journal PLOS Neglected Tropical Diseases.

Related Links:
Sacro Cuore - Don Calabria Hospital
Chembio Diagnostic Systems



New
Gold Member
Serological Pipets
INTEGRA Serological Pipets
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
DNA/RNA Extraction/Purification Kit
Nucleic Acid Extraction or Purification Kit
New
Gold Member
Pipette Management Software
VIALINK
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.